Trial Profile
Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Brilacidin (Primary) ; Daptomycin
- Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
- Focus Therapeutic Use
- Sponsors PolyMedix
- 21 Sep 2015 Results assessing population pharmacokinetics presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 21 Sep 2015 Population pharmacokinetics analysis results from this trial and an another trial presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.
- 26 Jan 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-003741-17).